And let's not forget the PD-L1 blockers which are
Post# of 154158
(Total Views: 282)
Posted On: 06/16/2025 2:33:07 AM
And let's not forget the PD-L1 blockers which are slightly different in their action but accomplish the same thing, acting as a primer for those killer T cells to activate:
Atezolizumab (Tecentriq): Developed by Genentech, which is part of the Roche group.
Avelumab (Bavencio): Developed by Merck KGaA (the German Merck), often associated with collaborative efforts in its distribution.
Durvalumab (Imfinzi): Manufactured by AstraZeneca.
Which also brings 3 more European companies into the picture, which could be important.
Atezolizumab (Tecentriq): Developed by Genentech, which is part of the Roche group.
Avelumab (Bavencio): Developed by Merck KGaA (the German Merck), often associated with collaborative efforts in its distribution.
Durvalumab (Imfinzi): Manufactured by AstraZeneca.
Which also brings 3 more European companies into the picture, which could be important.
(6)
(0)